Menu
← Oncology Approval Tracker
FDA DECISION ·
Emend for injection
fosaprepitant · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A three-day dosing option for prevention of chemotherapy-induced nausea and vomiting in eligible pediatric patients using intravenous Emend on day one.
LAMPGEN ANALYSIS
Why it matters
The supplemental decision adds an administration option for pediatric antiemetic prophylaxis.
What research teams should watch
Confirm the pediatric regimen and schedule all three days of antiemetic coverage around chemotherapy.
PRIMARY RECORDS